Chemistry:Fluoromedroxyprogesterone acetate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | FMPA; 9α-Fluoromedroxy |
| Routes of administration | By mouth |
| Drug class | Angiogenesis inhibitor; Progestogen; Progestogen ester; Progestin; Glucocorticoid |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H33FO4 |
| Molar mass | 404.522 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fluoromedroxyprogesterone acetate (FMPA, 9α-fluoromedroxyprogesterone acetate, or 9α-FMPA) is a synthetic steroid medication which was under development by Meiji Dairies Corporation in the 1990s and 2000s for the potential treatment of cancers but was never marketed.[1][2][3][4][5][6][7] It is described as an antiangiogenic agent, with about two orders of magnitude greater potency for inhibition of angiogenesis than its parent compound medroxyprogesterone acetate.[2][4][5] FMPA showed about the same affinities for the progesterone and glucocorticoid receptors as MPA.[4] It reached the preclinical phase of research prior to the discontinuation of its development.[1]
See also
References
- ↑ 1.0 1.1 "FMPA - AdisInsight". https://adisinsight.springer.com/drugs/800011224.
- ↑ 2.0 2.1 "Synthesis of a new potent anti-angiogenic agent, 17 alpha-acetoxy-9 alpha-fluoro-6 alpha-methylprogesterone (9 alpha-fluoromedroxyprogesterone acetate [FMPA])". Chem. Pharm. Bull. 45 (2): 421–3. February 1997. doi:10.1002/chin.199737217. PMID 9118456.
- ↑ "Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate". Biopharm Drug Dispos 20 (6): 277–84. September 1999. doi:10.1002/(SICI)1099-081X(199909)20:6<277::AID-BDD186>3.0.CO;2-T. PMID 10701698.
- ↑ 4.0 4.1 4.2 "Anti-angiogenic activity of a novel synthetic agent, 9alpha-fluoromedroxyprogesterone acetate". Cancer Lett. 145 (1–2): 107–14. October 1999. doi:10.1016/S0304-3835(99)00239-6. PMID 10530777.
- ↑ 5.0 5.1 "Inhibition by 9alpha-fluoromedoroxyprogesterone acetate (FMPA) against mammary carcinoma induced by dimethylbenz[a]anthracene in rats and angiogenesis in the rabbit cornea - comparison with medroxyprogesterone acetate (MPA)". Cancer Lett. 154 (1): 63–9. June 2000. doi:10.1016/S0304-3835(00)00375-X. PMID 10799740.
- ↑ "Synthesis and anti-tumor activity of a fluorinated analog of medroxyprogesterone acetate (MPA), 9alpha-fluoromedroxyprogesterone acetate (FMPA)". Chem. Pharm. Bull. 54 (11): 1567–70. November 2006. doi:10.1248/cpb.54.1567. PMID 17077554.
- ↑ "Suppression of laser-induced choroidal neovascularization by subconjunctival injection of 9alpha-fluoromedroxyprogesterone acetate (FMPA), an anti-angiogenic agent, in rats". Biol. Pharm. Bull. 29 (12): 2410–4. December 2006. doi:10.1248/bpb.29.2410. PMID 17142973.
External links
 |  |
